Viral and Non-Viral Vector Manufacturing Market Report 2026

The viral and non-viral vector manufacturing market size has grown exponentially in recent years. It will grow from $10.28 billion in 2025 to $12.4 billion in 2026 at a compound annual growth rate (CAGR) of 20.7%. The growth in the historic period can be attributed to advancements in gene therapy research, increasing clinical trial activity, expansion of biopharmaceutical manufacturing facilities, rising demand for viral vectors in oncology, availability of specialized manufacturing expertise.

The viral and non-viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $26.83 billion in 2030 at a compound annual growth rate (CAGR) of 21.3%. The growth in the forecast period can be attributed to increasing commercialization of gene and cell therapies, rising investments in vaccine development, expansion of CDMO partnerships, growing focus on scalable and flexible manufacturing, increasing regulatory approvals for advanced therapies. Major trends in the forecast period include increasing scale-up of viral vector production capacity, rising demand for non-viral delivery systems, growing adoption of modular manufacturing platforms, expansion of contract vector manufacturing services, enhanced focus on process standardization and quality control.

The rising number of clinical trials is expected to drive the growth of the viral and non-viral vector manufacturing markets in the coming years. Clinical trials are research studies conducted with human participants to assess the safety, efficacy, and potential side effects of a medical intervention, treatment, or drug. Viral and non-viral vector manufacturing plays a crucial role in supporting gene therapy clinical trials by supplying the necessary tools to deliver therapeutic genes to patients while ensuring the safety, quality, and scalability of these vectors throughout all trial phases. For instance, in December 2023, according to ClinicalTrials.gov, a US-based web resource maintained by the US National Library of Medicine, in 2022, a total of 437,515 clinical trials were registered, of which 56,561 were completed. By December 20, 2023, registration and completion figures had increased, with 476,626 clinical trials registered and 61,504 completed. Therefore, the rising number of clinical trials is propelling the growth of the viral and non-viral vector manufacturing markets.

Major companies operating in the viral and non-viral vector manufacturing market are focusing on partnerships to enhance profitability. Collaborative partnerships in viral and non-viral vector manufacturing involve biopharmaceutical companies, CDMOs, research institutions, and technology providers working together to improve the efficiency, safety, and scalability of non-viral vector development and production. For instance, in September 2023, NecstGen, a Netherlands-based CDMO providing comprehensive support for developers in the Cell and Gene Therapy sector, collaborated with ProteoNic BioSciences, a Netherlands-based technology provider for complex therapeutic protein production, to launch ProteoNic’s 2G UNic premium vector technology. This technology has enhanced the development of lentiviral (LV) vectors, increasing functional viral particle titers and improving process efficiency, thereby boosting the cost-effectiveness and accessibility of therapies. Its applications extend to gene therapy viral vector production, mRNA therapeutics, and transient protein production. By advancing AAV and LV viral vector manufacturing for both transient systems and stable producer cell lines, this technology benefits viral vector production for gene therapies and non-vector processes across multiple applications.

In March 2023, Sartorius, a Germany-based pharmaceutical and laboratory equipment supplier, acquired Polyplus for approximately $2.59 billion. Through this acquisition, Sartorius aims to strengthen its position in the gene therapy and viral vector production markets by expanding its cell and gene therapy capabilities. Polyplus is a France-based biotechnology company specializing in the manufacture of both viral and non-viral vectors for gene therapy applications.

Major companies operating in the viral and non-viral vector manufacturing market are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.

North America was the largest region in the viral and non-viral vector manufacturing market in 2025. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral and non-viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the viral and non-viral vector manufacturing market by increasing costs of imported bioreactors, raw materials, filtration systems, single-use technologies, and analytical equipment used in vector production. Biopharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported high-precision components, while Asia-Pacific faces higher setup costs for export-oriented facilities. These tariffs are raising capital expenditure and extending facility commissioning timelines. However, they are also encouraging domestic manufacturing investments, regional supplier development, and innovation in localized vector production capabilities.

The viral and non-viral vector manufacturing market research report is one of a series of new reports that provides viral and non-viral vector manufacturing market statistics, including viral and non-viral vector manufacturing industry global market size, regional shares, competitors with a viral and non-viral vector manufacturing market share, detailed viral and non-viral vector manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the viral and non-viral vector manufacturing industry. This viral and non-viral vector manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral and non-viral vector manufacturing involves the production of viral and non-viral vectors, which are tools used to deliver genetic material into cells. Viral vectors are employed in the treatment of human diseases and are widely used in anticancer and gene therapies. Non-viral vectors are used for various gene therapy applications, particularly in vaccine development and cancer treatment.

The main types of vectors in viral and non-viral vector manufacturing are viral vectors and non-viral vectors. A viral vector is a method commonly used in gene therapy and gene editing to introduce therapeutic genes or modify the expression of existing genes in living organisms. These vectors are applied to treat diseases such as cancer, genetic disorders, infectious diseases, cardiovascular diseases, and others, and are used in gene therapy, vaccinology, cell therapy, and related applications.

The viral and non-viral vector manufacturing market includes revenues earned by entities by providing adeno-associated viral vectors, lentiviral vectors, retroviral vectors, adenoviral vectors, particle-based vectors, and chemical-based vectors. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.